Riccardo Braglia

Riccardo Braglia

Chief Executive Officer | Helsinn Healthcare SA

Riccardo Braglia, Helsinn Group’s Vice Chairman and CEO, Managing Director and Member of Helsinn Holding’s Board of Directors, Switzerland and Executive Committee for Helsinn Group’s strategic management, has a wealth of over 30 years of international experience in the pharmaceutical industry. Mr. Braglia heads the family-run, privately owned pharmaceutical company, the Helsinn Group, founded in 1976, with a worldwide presence and focus on cancer therapeutics and supportive care. Mr. Braglia is a Board Member of Helsinn Healthcare, Switzerland, Helsinn Advanced Synthesis, Switzerland, Helsinn Birex Pharmaceuticals, Ireland and Chairman of Helsinn Therapeutics, USA. He is also Président Directeur Général – Gérant Associé of Helsinn International Services, Monaco, Principality of Monaco and Chairman of the Helsinn Investment Fund, Luxembourg. Mr. Braglia serves as a Board Member of two portfolio companies of the Helsinn Investment Fund, QuantumDx Group Limited, UK and GreenBone Ortho S.R.L., Italy. He is also Co-founder and Board Member of Lyfebulb, USA, and a Board Member of Thorne Research, Greenwich CT/USA, Wellness-Fx and Health Elements.com, all US companies. Mr. Braglia is a member of the Board of the Conquer Cancer Foundation, USA. Mr. Braglia is also active in the investment community as an advisor to the New York City-based venture capital firm Windham Ventures. Riccardo Braglia holds a degree in Business Economics with a specialization in Business Industrial Management from the Luigi Bocconi University of Milan, Italy.

Scroll to top